- Home
- RZLT vs SGHT Comparison
RZLT vs SGHT Comparison
Compare RZLT & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RZLT
- SGHT
- Stock Information
- Founded
- RZLT 2010
- SGHT 2011
- Country
- RZLT United States
- SGHT United States
- Employees
- RZLT N/A
- SGHT N/A
- Industry
- RZLT Biotechnology: Pharmaceutical Preparations
- SGHT Medical Specialities
- Sector
- RZLT Health Care
- SGHT Health Care
- Exchange
- RZLT Nasdaq
- SGHT Nasdaq
- Market Cap
- RZLT 292.0M
- SGHT 304.4M
- IPO Year
- RZLT N/A
- SGHT 2021
- Fundamental
- Price
- RZLT $5.18
- SGHT $3.87
- Analyst Decision
- RZLT Strong Buy
- SGHT Buy
- Analyst Count
- RZLT 8
- SGHT 7
- Target Price
- RZLT $11.63
- SGHT $6.58
- AVG Volume (30 Days)
- RZLT 393.1K
- SGHT 249.8K
- Earning Date
- RZLT 11-07-2024
- SGHT 11-07-2024
- Dividend Yield
- RZLT N/A
- SGHT N/A
- EPS Growth
- RZLT N/A
- SGHT N/A
- EPS
- RZLT N/A
- SGHT N/A
- Revenue
- RZLT N/A
- SGHT $79,543,000.00
- Revenue This Year
- RZLT N/A
- SGHT $2.18
- Revenue Next Year
- RZLT N/A
- SGHT $8.14
- P/E Ratio
- RZLT N/A
- SGHT N/A
- Revenue Growth
- RZLT N/A
- SGHT N/A
- 52 Week Low
- RZLT $0.76
- SGHT $2.58
- 52 Week High
- RZLT $6.19
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- RZLT 49.97
- SGHT 39.20
- Support Level
- RZLT $4.90
- SGHT $3.65
- Resistance Level
- RZLT $5.53
- SGHT $4.11
- Average True Range (ATR)
- RZLT 0.35
- SGHT 0.19
- MACD
- RZLT 0.01
- SGHT 0.06
- Stochastic Oscillator
- RZLT 59.77
- SGHT 27.50
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.